Financial
FY2025 revenue $77.3m (+19.0%); operating margin -91.7%; net loss $79.0m.
Balance sheet figures not captured from release.
SOPHiA GENETICS
HQ Switzerland · Europe
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Weak
Customer rating
No reviews yet
Financial health
Band: WeakListed: SOPH
FY2025 revenue $77.3m (+19.0%); operating margin -91.7%; net loss $79.0m.
Balance sheet figures not captured from release.
Source: official results release · Year ended 2025-12-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | US$77.3m | +19.0% | -US$70.9m | -US$79m | SOPHiA GENETICS |
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
No adverse media involving SOPHiA GENETICS found in HSH's search of the last 24 months. Jan 2026: it announced President Ross Muken would succeed co-founder Jurgi Camblong as CEO from 1 Jul 2026, with Camblong becoming Executive Chairman.
Cyber & information governance
No data breaches, cyber incidents or regulator actions involving SOPHiA GENETICS found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
No recalls, safety notices or regulator actions involving SOPHiA GENETICS found in HSH's search of the last 24 months.
Contract performance
May 2026: SOPHiA GENETICS and Synnovis (the GSTT/KCH pathology partnership) announced a partnership to offer liquid biopsy testing for lung and breast cancer under NHS England's blood test-first programme, projecting about 7,000 patients a year.
Competitors
No competitors linked yet.